 | |
- close
- close
|
StreetInsider.com
Feb 8
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Synta+Pharma+%28SNTA%29+Preclinical+Shows+STA-9090+Inhibits+Wilms%27+Tumor+1+Protein/5315793.html for the full story.
Business Wire
Feb 8
Comment
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of
Business Wire
Feb 1
Comment
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be presenting at the 2010 BIO CEO & Investor Conference on Monday, February 8 at 8:30 am (ET) at the Waldorf Astoria Hotel in New York. A live audio webcast and replay
Motley Fool
Jan 28
Comment
You don't need million to make millions. Just follow this simple four-step plan.
Business Wire
Jan 19
Comment
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the completion of the sale of 833,333 additional
Business Wire
Jan 12
Comment
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the
Business Wire
Jan 8
Comment
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the pricing of an underwritten public offering of
Business Wire
Jan 7
Comment
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it intends to offer, subject to market and
Business Wire
Dec 23
Comment
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of
Suggest other news sources for this topic
Thank you for your suggestion
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| ||||||
